Literature DB >> 24523121

Sources of interindividual variability.

Kenneth E Thummel1, Yvonne S Lin.   

Abstract

The efficacy, safety, and tolerability of drugs are dependent on numerous factors that influence their disposition. A dose that is efficacious and safe for one individual may result in sub-therapeutic or toxic blood concentrations in other individuals. A major source of this variability in drug response is drug metabolism, where differences in pre-systemic and systemic biotransformation efficiency result in variable degrees of systemic exposure (e.g., AUC, C max, and/or C min) following administration of a fixed dose.Interindividual differences in drug biotransformation have been studied extensively. It is well recognized that both intrinsic (such as genetics, age, sex, and disease states) and extrinsic (such as diet, chemical exposures from the environment, and even sunlight) factors play a significant role. For the family of cytochrome P450 enzymes, the most critical of the drug metabolizing enzymes, genetic variation can result in the complete absence or enhanced expression of a functional enzyme. In addition, up- and down-regulation of gene expression, in response to an altered cellular environment, can achieve the same range of metabolic function (phenotype), but often in a less reliably predictable and time-dependent manner. Understanding the mechanistic basis for drug disposition and response variability is essential if we are to move beyond the era of empirical, trial-and-error dose selection and into an age of personalized medicine that brings with it true improvements in health outcomes in the therapeutic treatment of disease.

Mesh:

Substances:

Year:  2014        PMID: 24523121     DOI: 10.1007/978-1-62703-758-7_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.

Authors:  Alison E Fohner; Renee Robinson; Joseph Yracheta; Denise A Dillard; Brian Schilling; Burhan Khan; Scarlett Hopkins; Bert Boyer; Jynene Black; Howard Wiener; Hemant K Tiwari; Adam Gordon; Deborah Nickerson; Jesse M Tsai; Federico M Farin; Timothy A Thornton; Allan E Rettie; Kenneth E Thummel
Journal:  Pharmacogenet Genomics       Date:  2015-07       Impact factor: 2.089

2.  Chronic, low-level oral exposure to marine toxin, domoic acid, alters whole brain morphometry in nonhuman primates.

Authors:  Rebekah Petroff; Todd Richards; Brenda Crouthamel; Noelle McKain; Courtney Stanley; Kimberly S Grant; Sara Shum; Jing Jing; Nina Isoherranen; Thomas M Burbacher
Journal:  Neurotoxicology       Date:  2019-02-28       Impact factor: 4.294

3.  Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells.

Authors:  Mei-Mei Li; Wei-Peng Wang; Wen-Juan Wu; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2014-08-26       Impact factor: 3.922

4.  LightSNiP assay is a good strategy for pharmacogenetics test.

Authors:  Stefania Cheli; Filippo Pietrantonio; Emilio Clementi; Felicia S Falvella
Journal:  Front Pharmacol       Date:  2015-06-02       Impact factor: 5.810

5.  Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology.

Authors:  A A Seyerle; C M Sitlani; R Noordam; S M Gogarten; J Li; X Li; D S Evans; F Sun; M A Laaksonen; A Isaacs; K Kristiansson; H M Highland; J D Stewart; T B Harris; S Trompet; J C Bis; G M Peloso; J A Brody; L Broer; E L Busch; Q Duan; A M Stilp; C J O'Donnell; P W Macfarlane; J S Floyd; J A Kors; H J Lin; R Li-Gao; T Sofer; R Méndez-Giráldez; S R Cummings; S R Heckbert; A Hofman; I Ford; Y Li; L J Launer; K Porthan; C Newton-Cheh; M D Napier; K F Kerr; A P Reiner; K M Rice; J Roach; B M Buckley; E Z Soliman; R de Mutsert; N Sotoodehnia; A G Uitterlinden; K E North; C R Lee; V Gudnason; T Stürmer; F R Rosendaal; K D Taylor; K L Wiggins; J G Wilson; Y-Di Chen; R C Kaplan; K Wilhelmsen; L A Cupples; V Salomaa; C van Duijn; J W Jukema; Y Liu; D O Mook-Kanamori; L A Lange; R S Vasan; A V Smith; B H Stricker; C C Laurie; J I Rotter; E A Whitsel; B M Psaty; C L Avery
Journal:  Pharmacogenomics J       Date:  2017-07-18       Impact factor: 3.550

6.  A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-24

7.  'The same old story': thoughts on authorized doses of anticancer drugs.

Authors:  Fausto Meriggi; Alberto Zaniboni
Journal:  Ther Adv Med Oncol       Date:  2020-02-22       Impact factor: 8.168

Review 8.  Frequencies of CYP2D6 genetic polymorphisms in Arab populations.

Authors:  Mousa Alali; Wouroud Ismail Al-Khalil; Sara Rijjal; Lana Al-Salhi; Maher Saifo; Lama A Youssef
Journal:  Hum Genomics       Date:  2022-02-05       Impact factor: 4.639

9.  Stress as a Potential Regulatory Factor in the Outcome of Pharmacotherapy.

Authors:  Maria Konstandi; Elizabeth O Johnson; Matti A Lang
Journal:  Front Neurosci       Date:  2022-03-23       Impact factor: 4.677

10.  Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness.

Authors:  Tamim Ahsan; Nusrat Jahan Urmi; Abu Ashfaqur Sajib
Journal:  PLoS One       Date:  2020-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.